Clinical Genomics Market Share

Global Clinical Genomics Market Overview

Clinical Genomics Market Size was valued at USD 0.8 Billion in 2022. The Clinical genomics market industry is projected to grow from USD 0.9 Billion in 2023 to USD 3.41 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 17.50% during the forecast period (2023 - 2032). Advancements in genomic sequencing technologies and precision medicine are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Clinical Genomics Market Trends

• Increasing prevalence of genetic disorders is driving the market growth

The creation of thorough genomic databases and archives was required due to the rising prevalence of genetic illnesses. Large amounts of genomic data are stored in these archives, which aid in the pattern and association finding process for academics and medical experts. These databases are essential for academics looking for prospective treatment targets as well as physicians trying to make accurate diagnoses.

Research and development in the field of pharmacogenomics have been sparked by the rising prevalence of genetic diseases. This area of study focuses on comprehending how a person's genetic composition affects how they react to drugs. Pharmacogenomic insights are essential for personalizing medication therapy for individuals with genetic disorders as well as those with other medical problems in order to achieve the best results with the fewest side effects. The potential to improve patient care and therapeutic efficacy at this nexus of clinical genomics and pharmacogenomics is enormous.

Healthcare systems and governments are giving higher priority to genetic screening and testing programs as a result of the growing public awareness of genetic illnesses, often raised by advocacy groups and patient communities. To enable early intervention and management, babies are frequently examined for a panel of genetic diseases shortly after delivery. These screening programs are anticipated to rise as the number of genetic illnesses detected increases, generating a persistent need for clinical genomics services and knowledge.

Genetic problems are common, which has increased interest in family planning and reproductive health. To make educated decisions about having children, couples with a history of genetic abnormalities or with higher genetic risk factors are getting preconception genetic testing and counseling. Reproductive genomics is a rising business niche within clinical genomics as a result of this trend. Reproductive genomics provides insights into family genetics, risk assessment, and assisted reproductive technologies. Thus, driving the Clinical genomics market revenue.

Clinical Genomics Market Segment Insights

Clinical genomics Test Type Insights

The Clinical genomics market segmentation, based on test type, includes diagnostic testing, genetic testing, newborn screening, pre-implantation testing, prenatal testing, carrier testing and other tests. The diagnostic testing segment dominated the market in 2022. The demand for diagnostic testing has been driven by the rising prevalence of both rare and common genetic illnesses. Various tests are crucial for locating the genetic abnormalities that cause various ailments, allowing for early detection and individualized treatment regimens.

Clinical genomics Method Insights

The Clinical genomics market segmentation, based on method, includes molecular tests, chromosomal tests and biochemical tests. The biochemical tests segment dominated the market in 2022. The diagnosis of different genetic problems, metabolic diseases, and other medical issues requires the use of biochemical testing. These exams aid in the discovery of particular biomarkers or aberrant concentrations of metabolites, proteins, or enzymes that point to the presence of a disease. The need for continual testing is increased by the fact that they are also used to track illness development and therapy success.

Clinical genomics End User Insights

The Clinical genomics market segmentation, based on end user, includes hospitals & clinics, government laboratories & research centres, academics and research institutes and other end users. The hospitals & clinics category generated the most income in 2022. Patients are taking a more active role in taking control of their health, and they are becoming more and more interested in individualized treatment. They look for medical facilities, such as clinics and hospitals that can do genomic testing and evaluate genetic data to create treatment programs that are specific to each patient's genetic profile.

Figure 1: Clinical Genomics Market, by end user, 2022 & 2032 (USD Billion)

 Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Clinical genomics Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Clinical Genomics Market dominated this market in 2022 (45.80%). Numerous prestigious universities, research centers, and biotechnology firms are located in North America, and they all actively contribute to the development of clinical genomics. These organizations pioneer genomic applications in healthcare, conduct cutting-edge genomics research, and create innovative technology. Further, the U.S. Clinical genomics market held the largest market share, and the Canada Clinical genomics market was the fastest growing market in the North America region.

Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: CLINICAL GENOMICS MARKET SHARE BY REGION 2022 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Clinical genomics market accounts for the second-largest market share. More and more European nations are realizing how important it is to offer their inhabitants genetic testing and counseling services. In many hospitals and clinics around Europe, genetic testing is available, and patients can get genetic counseling to better understand their risks and make decisions. Further, the German Clinical genomics market held the largest market share, and the UK Clinical genomics market was the fastest growing market in the European region.

The Asia-Pacific Clinical Genomics Market is expected to grow at the fastest CAGR from 2023 to 2032. Numerous prestigious academic and research institutions that carry out cutting-edge genomics research can be found throughout the Asia-Pacific area. These organizations encourage innovation, promote the creation of novel genomic technologies, and cultivate a workforce with expertise in genomics and bioinformatics. Moreover, China’s Clinical genomics market held the largest market share, and the Indian Clinical genomics market was the fastest growing market in the Asia-Pacific region.

Clinical genomics Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Clinical genomics market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Clinical genomics industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Clinical genomics industry to benefit clients and increase the market sector. In recent years, the Clinical genomics industry has offered some of the most significant advantages to medicine. Major players in the Clinical genomics market, including Quest Diagnostics Incorporated (U.S.), Eurofins Scientific SE (Luxembourg), Illumina, Inc. (U.S.), PerkinElmer, Inc. (U.S.), NeoGenomics Inc. (U.S.), Foundation Medicine, Inc. (U.S.), Rosetta Genomics Ltd. (Israel), Invitae Corporation (U.S.), Myriad Genetics, Inc. (U.S.), Natera, Inc. (U.S.), Genomic Health, Inc. (U.S.), OPKO Health, Inc. (U.S.), Centogene AG (Germany), Clinical Genomics Pty Ltd. (Australia), 23andMe, Inc. (U.S.), Iverson Genetic Diagnostics, Inc. (U.S.), Veritas Genetics (U.S.), Gene by Gene, Ltd. (U.S.), GenomeDx Biosciences, Inc. (Canada), MedGenome (India), Strand Life Sciences Pvt. Ltd. (India), Beijing Genomics Institute (BGI) (China), Retrogen, Inc. (U.S.), Personalis, Inc. (U.S.), and PathGroup (U.S.) and others, are attempting to increase market demand by investing in research and development operations.

Analytical testing services are provided to clients in a variety of industries by a life sciences company called Eurofins Scientific SE (Eurofins). The company offers a variety of services including forensics, environmental testing, agroscience, biopharma, pharmaceutical discovery, early development, pharmaceutical central laboratory, biopharma product testing, and product testing. Its analytical methods help in figuring out whether biological products and chemicals are pure, real, and safe. It draws on its knowledge in logistics and information technology to offer a range of services. The company has activities in North America, South America, the Middle East, Asia Pacific, and Europe. Eurofins' main office is in Luxembourg.

OPKO Health Inc (OPKO) researches, creates, produces, and sells innovative pharmaceutical and diagnostic products. The company's product line includes the Claros analyzer, a blood performance test, the Rayaldee (calcifediol), an extended-release capsule for the treatment of secondary hyperparathyroidism in patients with stage 3 or stage 4 chronic kidney disease. The Carboxyl Terminal Peptide (CTP), Reversible PEGylation, and AntagoNAT technologies, among others, are unique to OPKO. The pipeline items it is advancing are meant to address conditions like hypophosphatemia, diabetes, obesity, haemophilia, insufficient growth hormone, dravet syndrome, and others. Additionally, it sells veterinary supplies. With offices in Chile, Mexico, Spain, Ireland, Canada, and Israel, the corporation is operationally present. Miami, Florida is home to OPKO's headquarters in the US.

Key Companies in the Clinical genomics market include

• 
  

  Quest Diagnostics Incorporated (U.S.)

  
  


• 
  

  Eurofins Scientific SE (Luxembourg)

  
  


• 
  

  Illumina, Inc. (U.S.)

  
  


• 
  

  PerkinElmer, Inc. (U.S.)

  
  


• 
  

  NeoGenomics Inc. (U.S.)

  
  


• 
  

  Foundation Medicine, Inc. (U.S.)

  
  


• 
  

  Rosetta Genomics Ltd. (Israel)

  
  


• 
  

  Invitae Corporation (U.S.)

  
  


• 
  

  Myriad Genetics, Inc. (U.S.)

  
  


• 
  

  Natera, Inc. (U.S.)

  
  


• 
  

  Genomic Health, Inc. (U.S.)

  
  


• 
  

  OPKO Health, Inc. (U.S.)

  
  


• 
  

  Centogene AG (Germany)

  
  


• 
  

  Clinical Genomics Pty Ltd. (Australia)

  
  


• 
  

  23andMe, Inc. (U.S.)

  
  


• 
  

  Iverson Genetic Diagnostics, Inc. (U.S.)

  
  


• 
  

  Veritas Genetics (U.S.)

  
  


• 
  

  Gene by Gene, Ltd. (U.S.)

  
  


• 
  

  GenomeDx Biosciences, Inc. (Canada)

  
  


• 
  

  MedGenome (India)

  
  


• 
  

  Strand Life Sciences Pvt. Ltd. (India)

  
  


• 
  

  Beijing Genomics Institute (BGI) (China)

  
  


• 
  

  Retrogen, Inc. (U.S.)

  
  


• 
  

  Personalis, Inc. (U.S.)

  
  


• 
  

  PathGroup (U.S.)

  
  

Clinical genomics Industry Developments

August 2022:Modern R&D and manufacturing facilities were used by Trivitron Healthcare to open the Center of Excellence in India. This center will carry out research and innovation in a variety of fields, including genomics.

July 2022:Replay was established with seed funding of USD 55 million with the goal of transforming genetic medicine through interconnected technological platforms. A multinational syndicate of investors, including KKR, OMX Ventures, ARTIS Ventures, and Landsdowne Partners, is supporting the launch.

February 2023:A revolutionary test for the expansion and persistence of Chimeric Antigen Receptor T-Cell (CAR-T) therapy in patients with pre-B cell acute lymphoblastic leukemia and B cell lymphomas has begun, according to Eurofins Viracor.

Clinical Genomics Market Segmentation

Clinical genomics Test Type Outlook

• 
  

  Diagnostic Testing

  
  


• 
  

  Genetic Testing

  
  


• 
  

  Newborn Screening

  
  


• 
  

  Preimplantation Testing

  
  


• 
  

  Prenatal Testing

  
  


• 
  

  Carrier Testing

  
  


• 
  

  Other Tests

  
  

Clinical genomics Method Outlook

• 
  

  Molecular Tests

  
  


• 
  

  Chromosomal Tests

  
  


• 
  

  Biochemical Tests

  
  

Clinical genomics End User Outlook

• 
  

  Hospitals & Clinics

  
  


• 
  

  Government Laboratories & Research Centres

  
  


• 
  

  Academics and Research Institutes

  
  


• 
  

  Other End Users

  
  

Clinical genomics Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America